Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide with R-GemOx(rituximab、gemcitabine plus oxaliplatin) regimen in the treatment of transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
DRUG: Chidamide, Rituximab, Gemcitabine,Oxaliplatin
ORR, the proportion of patients who had CR, and PR according to the revised 2014 Lugano criteria for response assessment of lymphoma., 4-years
DOR, the time from the first CR or PR to the first documented progressive disease (PD) or death, whichever occurred earlier., 4-years|PFS, the time from the date of enrollment until either PD or death., 4-years|OS, the time from the date of enrollment until death, 4-years
bio-marker analysis, Correlation between epigenetic factor mutation and efficacy, 4-years
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide with R-GemOx(rituximab、gemcitabine plus oxaliplatin) regimen in the treatment of transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.